When creating groundbreaking health care technology, keeping products user friendly is a necessity. Photo via Getty Images

In the vibrant landscape of startups, the quest to build groundbreaking products can sometimes overshadow the true essence of our existence — to solve problems for our customers.

It's a trap many fall into, often leading to two common outcomes: prolonged product launches stretching over years or an unfortunate mismatch between product and market leading to startup death. But a dynamic solution exists, minimum viable products, or MVPs. MVP has propelled startups to unprecedented success.

A real-life testimony: MVP's power

Imagine a health care-focused at-home testing startup partnered with a major player. The aim: a telehealth support system for the at-home colon cancer screening. Unlike traditional telehealth services, this system required guiding members through a complex process of collecting stool samples accurately.

Challenges presented

  • Develop a user-friendly telehealth solution in five to six weeks on a limited budget and secure a high-stakes multimillion-dollar deal.
  • Carefully integrating telehealth on the existing portal for user-friendly access while aligning seamlessly with user expectations.
  • Address the complexities of Telehealth, including clinician staffing and regulatory adherence.

User Insights

User journeys and interviews confirmed the necessity for guided support during test-taking, but users showed reluctance to navigate the process independently and expressed a preference for customer support over a clinician assistant.

Interestingly, telehealth was not instinctively linked to test support, but rather to medical advice.

The birth of an MVP strategy: a catalyst for innovation

Since the main user problem was the guided support during test-taking, we created the following MVP solutions.

  • Video call integration: Direct video call button under customer support.
  • Guided messaging: Articulate call support purpose.
  • Testing guides: Portal's step-by-step guidance with videos.
  • Video guide in test kit materials.

Our MVP led us to an excellent NPS score and became a guide for our future roadmap.

Next time you build, remember this and embrace the dynamic MVP strategy — create, learn, and reiterate are the cornerstones of success in digital health product management's journey.

Here are four steps for building a successful MVP in telehealth.

  • Identify crucial user problems: Pinpoint your target customers' most pressing issue.
  • Solve a small problem simply: Initiate a straightforward solution to address a minor problem.
  • Plot the user's journey: Map out the user's path through your solution.
  • Prioritize ruthlessly: Discern the key features and prioritize with precision.
------

Tanu Jain is the founder and CEO of Houston-based Digital Health Innovator, a strategic marketing firm for health care products.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”